Clinical Trial Detail

NCT ID NCT02124148
Title A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company
Indications

breast cancer

Advanced Solid Tumor

colorectal cancer

Therapies

Cisplatin + Prexasertib

Cetuximab + Prexasertib

Pemetrexed Disodium + Prexasertib

LY3023414 + Prexasertib

Fluorouracil + Leucovorin + Prexasertib

Age Groups: adult senior

Additional content available in CKB BOOST